Poliovirus vaccine trial shows early promise for recurrent glioblastoma

May 21, 2013

An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

The treatment, developed at Duke and tested in an ongoing phase 1 study, capitalizes on the discovery that have an abundance of receptors that work like magnets drawing the , which then infects and kills the cells.

The investigational therapy, known as PVSRIPO, uses an engineered form of the virus that is lethal to cancer cells, while harmless to normal cells. Infused directly into the patient's tumor, the virus-based therapy also triggers the body's immune fighters to launch an attack against the infected .

Preliminary data, presented at the upcoming 2013 Annual Meeting of the in Chicago (ASCO abstract #2094), previews the results of seven patients enrolled in the study whose tumors reoccurred despite traditional treatments for glioblastoma multiforme, the most common and aggressive brain tumor.

Of the patients enrolled in the study, three have responded well to the drug. One patient remains disease-free 12 months after treatment, another 11 months post-treatment and the third is disease-free after five months. With traditional treatment, about half of glioblastoma patients see recurrent within eight weeks.

Two patients in the study did not fair as well; one had recurrent tumor growth after two months, and another's condition declined after four months. The remaining two patients have been treated in the last three and two months, respectively, and currently remain disease free.

"These early results are intriguing," said Annick Desjardins, M.D., FRCPC, principal investigator and associate professor of medicine at Duke University School of Medicine. "Current therapies for glioblastoma are limited because they cannot cross the blood-brain barrier and often do not specifically attack the tumor. This treatment appears to overcome those problems. We are eager to see additional results as we move forward with our study."

Explore further: UC Irvine opens clinical trial of novel treatment for brain cancer

Related Stories

UC Irvine opens clinical trial of novel treatment for brain cancer

October 10, 2012
UC Irvine doctors are enrolling patients with the deadly brain tumor glioblastoma multiforme in a clinical trial of a vaccine that may prevent the cancer's return or spread after surgery.

Gauging brain cancer survival time may get easier, study says

April 10, 2013
(HealthDay)—Life expectancy of people with aggressive brain cancer may be easier to determine with a new method under development at the University of Alabama at Birmingham, researchers say.

Brain cancer breakthrough: Experimental vaccine trains immune system to target remaining tumor cells after surgery

November 14, 2012
UC Irvine oncologists are looking for new ways to treat glioblastoma multiforme, the deadliest type of brain cancer. While surgery followed by chemotherapy and radiation is the current standard of care, it doesn't fully eliminate ...

Study finds new targets for drugs to defeat aggressive brain tumor

December 14, 2012
University of Pittsburgh Cancer Institute (UPCI) researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line, which could offer new hope for drug treatment to destroy ...

A culprit behind brain tumor resistance to therapy

March 5, 2012
Persistent protein expression may explain why tumors return after therapy in glioblastoma patients, according to a study published on March 5th in the Journal of Experimental Medicine.

New anti-tumor cell therapy strategies are more effective

October 25, 2012
Targeted T-cells can seek out and destroy tumor cells that carry specific antigen markers. Two novel anti-tumor therapies that take advantage of this T-cell response are described in articles published in Human Gene Therapy, ...

Recommended for you

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.